Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates

分组1 - Illumina reported quarterly earnings of $1.35 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and showing an increase from $0.86 per share a year ago, resulting in an earnings surprise of +7.42% [1] - The company achieved revenues of $1.16 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.35% and increasing from $1.1 billion year-over-year [2] - Illumina has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 2.3% since the beginning of the year, outperforming the S&P 500, which has gained 0.5% [3] - The future performance of Illumina's stock will depend on management's commentary during the earnings call and the earnings outlook for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $1.11 on revenues of $1.07 billion, and for the current fiscal year, it is $5.08 on revenues of $4.44 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Illumina belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8] - The correlation between near-term stock movements and earnings estimate revisions is strong, indicating that tracking these revisions can be beneficial for investors [5]